Based on the key indicators related to ProPhase Labs' liquidity, profitability, solvency, and operating efficiency, ProPhase Labs is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February. As of now, ProPhase Labs' Accounts Payable is increasing as compared to previous years. The ProPhase Labs' current Non Current Assets Total is estimated to increase to about 39.3 M, while Total Assets are projected to decrease to under 36.6 M. Key indicators impacting ProPhase Labs' financial strength include:
The essential information of the day-to-day investment outlook for ProPhase Labs includes many different criteria found on its balance sheet. An individual investor should monitor ProPhase Labs' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in ProPhase Labs.
ProPhase Labs competes with Aytu BioScience, TherapeuticsMD, Allurion Technologies, Eterna Therapeutics, and Biofrontera. ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter consumer healthcare products and dietary supplements in the United States. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. Prophase Labs operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 129 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining ProPhase Labs's current stock value. Our valuation model uses many indicators to compare ProPhase Labs value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ProPhase Labs competition to find correlations between indicators driving ProPhase Labs's intrinsic value. More Info.
ProPhase Labs is rated below average in return on equity category among its peers. It is regarded fifth in return on asset category among its peers . As of now, ProPhase Labs' Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ProPhase Labs' earnings, one of the primary drivers of an investment's value.
ProPhase Labs Systematic Risk
ProPhase Labs' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. ProPhase Labs volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on ProPhase Labs correlated with the market. If Beta is less than 0 ProPhase Labs generally moves in the opposite direction as compared to the market. If ProPhase Labs Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one ProPhase Labs is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of ProPhase Labs is generally in the same direction as the market. If Beta > 1 ProPhase Labs moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in ProPhase Labs Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ProPhase Labs' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of ProPhase Labs growth as a starting point in their analysis.
Along with financial statement analysis, the daily predictive indicators of ProPhase Labs help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of ProPhase Labs. We use our internally-developed statistical techniques to arrive at the intrinsic value of ProPhase Labs based on widely used predictive technical indicators. In general, we focus on analyzing ProPhase Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build ProPhase Labs's daily price indicators and compare them against related drivers.
When running ProPhase Labs' price analysis, check to measure ProPhase Labs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProPhase Labs is operating at the current time. Most of ProPhase Labs' value examination focuses on studying past and present price action to predict the probability of ProPhase Labs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProPhase Labs' price. Additionally, you may evaluate how the addition of ProPhase Labs to your portfolios can decrease your overall portfolio volatility.